BHVN240719C35000
- 1.90
- +0.35+22.58%
Biohaven Newsroom
TD Cowen Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $55
TD Cowen analyst Tyler Van Buren maintains $Biohaven(BHVN.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 41.9% and a total average return of -1.2% over the past y
Biohaven(BHVN.US) Officer Buys US$1.01 Million in Common Stock
$Biohaven(BHVN.US)$ Officer Car Bruce purchased 30,000 shares of common stock on Jun 17, 2024 at an average price of $33.583 for a total value of $1.01 million.Source: Announcement What is statement o
RBC Capital Reiterates Outperform on Biohaven, Maintains $59 Price Target
RBC Capital analyst Leonid Timashev reiterates Biohaven (NYSE:BHVN) with a Outperform and maintains $59 price target.
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $59
RBC Capital analyst Leonid Timashev maintains $Biohaven(BHVN.US)$ with a buy rating, and maintains the target price at $59.According to TipRanks data, the analyst has a success rate of 33.3% and a tot
Express News | NYSE Order Imbalance 50369.0 Shares on Buy Side
Biohaven Insider Bought Shares Worth $996,240, According to a Recent SEC Filing
John W Childs, Director, on May 30, 2024, executed a purchase for 28,000 shares in Biohaven (BHVN) for $996,240. Following the Form 4 filing with the SEC, Childs has control over a total of 6,432,244
Biohaven(BHVN.US) Director Buys US$996.24K in Common Stock
$Biohaven(BHVN.US)$ Director CHILDS JOHN W purchased 28,000 shares of common stock on May 30, 2024 at an average price of $35.58 for a total value of $996.24K.Source: Announcement What is statement of
Buy Rating Affirmed for Biohaven Ltd. Amidst Expansion and Progress in R&D Programs
HC Wainwright & Co. : The Biohaven (BHVN.US) rating was reaffirmed, adjusted from buy to buy rating, and the target price was adjusted from $59.00 to $59.00.
HC Wainwright & Co. : The Biohaven (BHVN.US) rating was reaffirmed, adjusted from buy to buy rating, and the target price was adjusted from $59.00 to $59.00.
HC Wainwright & Co. Reiterates Buy on Biohaven, Maintains $59 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Buy and maintains $59 price target.
Cantor Fitzgerald Corp.: Reiterates Biohaven's (BHVN.US) shareholding rating.
Cantor Fitzgerald Corp.: Reiterates Biohaven's (BHVN.US) shareholding rating.
Cantor Fitzgerald Reiterates Overweight on Biohaven
Cantor Fitzgerald analyst Charles Duncan reiterates Biohaven (NYSE:BHVN) with a Overweight.
Biohaven Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/30/2024 — Cantor Fitzgerald Reiterates → Overweight 05/13/2024 74.2% HC Wainwright & Co. $63 → $59 Mai
Goldman Sachs Raises Obesity Drug Market Estimate to $130B
HP Posts Upbeat Earnings, Joins Foot Locker, American Superconductor, Red Robin Gourmet Burgers And Other Big Stocks Moving Higher On Thursday
U.S. stocks were lower, with the Dow Jones index falling around 1% on Thursday.Shares of HP Inc. (NYSE:HPQ) rose sharply during Thursday's session following better-than-expected second-quarter financi
Analysts Conflicted on These Healthcare Names: NeueHealth Inc (NEUE), BridgeBio Pharma (BBIO) and Biohaven Ltd. (BHVN)
Biohaven Ltd. (BHVN) Gets a Buy From RBC Capital
Optimistic Outlook: Buy Rating Affirmed for Biohaven Ltd. Amid Promising Pipeline and Synergistic Drug Potential
Biohaven Doses First Subject in Phase I/II Tumour Treatment Study
Biohaven Shares Are Trading Lower After the Company Announced Pipeline and Portfolio Updates.
Biohaven Shares Are Trading Lower After the Company Announced Pipeline and Portfolio Updates.